The ongoing COVID‐19 pandemic has raised concerns regarding the outcome of this infection in patients with autoimmune bullous dermatoses (AIBDs) due to effect of drugs used to treat these disorders. This investigation was performed from the onset of the pandemic to June 1, 2021. Patients with AIBDs who contracted COVID‐19 were evaluated. A generalized linear model was employed to find the predictors of severe COVID‐19 among patients with AIBDs. Ninety‐three patients with AIBDs with a mean age of 50.3 years were evaluated. The most COVID‐19 related symptoms were tiredness (76.3%) myalgia (69%), and cough (63.4%). During follow‐up, the rate of hospitalization and death were 45.2% and 4.3%, respectively. Previous comorbidities (β = 0.61) and mean prednisolone dosage above 10 mg/day in the last 3 months (
β
= 1.10) significantly increased COVID‐19 severity. Also, vaccination against SARS‐CoV‐2 (
β
= −1.50) and each passing month from the last rituximab dose decreased severity (
β
= −0.02). Notably, 19.3% of the patients developed AIBD flare‐ups following COVID‐19 infection. Higher prednisone dose and the shorter interval from the last rituximab infusion were determinants of severe COVID‐19. Physicians should assess the risk versus the benefits when prescribing the medications. Moreover, vaccination could successfully attenuate COVID‐19 severity.
Pemphigus vulgaris (PV) is a rare, potentially life-threatening IgGmediated autoimmune disease of stratified squamous epithelia of skin and mucosa. IgG autoantibodies produced against desmoglein 3 and
As mass immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is being performed with vaccines on various platforms, a growing number of skin reactions have been attributed to these vaccines. Besides the most commonly reported
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.